INCY peer analysis
Incyte (INCY) against its competitors: price, today's move, 1-year return and market value side by side.
INCY and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| AVBP ArriVent BioPharma | $13.33 | -10.36% | -27.83% | – |
| CGEM Cullinan Therapeutics | $14.93 | -0.70% | 97.42% | – |
| EXEL Exelixis | $70.09 | 1.02% | 80.01% | $16.93B |
| GMAB Genmab | $54.93 | -3.73% | 91.59% | $35.09B |
| LEGN Legend Biotech | $21.11 | -2.40% | -34.54% | $4.21B |
| LGND Ligand Pharmaceuticals | $307.23 | -4.81% | 64.24% | $6.43B |
| NRIX Nurix Therapeutics | $25.70 | -4.09% | 101.13% | – |
| REGN Regeneron | $961.34 | 3.60% | 46.98% | $95.99B |
| SLS SELLAS Life Sciences | $8.51 | -12.09% | 345.55% | $1.95B |
| VSTM Verastem | $9.60 | -1.54% | 4.01% | $1.18B |
| INCY Incyte | $119.99 | -0.33% | 29.59% | $24.54B |
- INCY's peers: AVBP (ArriVent BioPharma), CGEM (Cullinan Therapeutics), EXEL (Exelixis), GMAB (Genmab), LEGN (Legend Biotech), LGND (Ligand Pharmaceuticals), NRIX (Nurix Therapeutics), REGN (Regeneron).
Updated 2026-11-03 00:13 UTC